up-to-date with a click!
Update December, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.
The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications December 2018

Add on treatments

  1. Singh F, Zoll J, Duthaler U et al. PGC-1beta modulates statin-associated myotoxicity in mice. Archives of toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511338
  2. Pais P, Jung H, Dans A et al. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. Eur J Prev Cardiol 2018:2047487318819019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30537846
  3. Gosho M. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis. Fundamental & clinical pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30575126
  4. Zhang H, Cui Y, Zhao Y et al. Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research : official journal of the Japanese Society of Hypertension 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552406
  5. Ahmed O, Littmann K, Gustafsson U et al. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. J Am Heart Assoc 2018; 7:e009876. http://www.ncbi.nlm.nih.gov/pubmed/?term=30561264
  6. Akbari H, Asadikaram G, Vakili S, Masoumi M. Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30548657
  7. Lorza-Gil E, de Souza JC, Garcia-Arevalo M et al. Coenzyme Q10 protects against beta-cell toxicity induced by pravastatin treatment of hypercholesterolemia. Journal of cellular physiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30536661
  8. Pahor M, Anton SD, Beavers DP et al. Effect of losartan and fish oil on plasma IL-6 and mobility in older persons. The ENRGISE Pilot randomized clinical trial. J Gerontol A Biol Sci Med Sci 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30541065
  9. Choi HD, Chae SM. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e13593. http://www.ncbi.nlm.nih.gov/pubmed/?term=30558030
  10. Sahebkar A, Simental-Mendia LE, Pirro M et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Scientific reports 2018; 8:17887. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552391

Adherence

  1. Buhse S, Kuniss N, Liethmann K et al. Informed shared decision-making programme for patients with type 2 diabetes in primary care: cluster randomised controlled trial. BMJ Open 2018; 8:e024004. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552272
  2. Hemo B, Shahar DR, Geva D, Heymann AD. Adherence to quality of care measurements among 58,182 patients with new onset diabetes and its association with mortality. PLoS One 2018; 13:e0208539. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540832
  3. Kamal AK, Khalid W, Muqeet A et al. Making prescriptions "talk" to stroke and heart attack survivors to improve adherence: Results of a randomized clinical trial (The Talking Rx Study). PLoS One 2018; 13:e0197671. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571697
  4. Hines DM, Rane P, Patel J et al. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag 2018; 14:409-418. http://www.ncbi.nlm.nih.gov/pubmed/?term=30573963

Atherosclerosis & Imaging

  1. Lee SH, Choi JH. Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy. Animal cells and systems 2018; 22:390-399. http://www.ncbi.nlm.nih.gov/pubmed/?term=30533261
  2. Alshaikh HN, Bohsali F, Gani F et al. Statin intensity and postoperative mortality following open repair of intact abdominal aortic aneurysm. BJS open 2018; 2:411-418. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511041
  3. Shirahama R, Ono T, Nagamatsu S et al. Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation. Intern Med 2018; 57:3551-3557. http://www.ncbi.nlm.nih.gov/pubmed/?term=30555118
  4. Shiga Y, Miura SI, Nishikawa H et al. Regression of coronary plaque after coronary artery bypass graft. Journal of cardiology cases 2012; 5:e92-e95. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532913
  5. Yamaguchi K, Wakatsuki T, Niki T et al. Observation of short-term atorvastatin-induced changes in coronary arterial plaque properties using integrated backscatter intravascular ultrasound in a patient. Journal of cardiology cases 2011; 3:e111-e114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532851
  6. Zhang Y, Fang Q, Niu K et al. Time-dependently slow-released multiple-drug eluting external sheath for efficient long-term inhibition of saphenous vein graft failure. J Control Release 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30521829
  7. Zhu YC, Jiang XZ, Bai QK et al. Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563776
  8. Feldman MD, Cabe AG, Milner TE. IVOCT Has a Bright Future in the Identification of Vulnerable Plaques. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503625
  9. Raber L, Koskinas KC, Yamaji K et al. Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30553686
  10. Xiao Y, He S, Zhang Z et al. Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies. Medical science monitor : international medical journal of experimental and clinical research 2018; 24:9166-9176. http://www.ncbi.nlm.nih.gov/pubmed/?term=30557296
  11. Cho YK, Nam CW, Koo BK et al. Usefulness of baseline statin therapy in non-obstructive coronary artery disease by coronary computed tomographic angiography: From the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) study. PLoS One 2018; 13:e0207194. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540755

Atorvastatin/Rosuvastatin

  1. Hasanvand A, Ahmadizar F, Abbaszadeh A et al. The Antinociceptive Effects of Rosuvastatin in Chronic Constriction Injury Model of Male Rats. Basic and clinical neuroscience 2018; 9:251-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=30519383
  2. Gurzeler E, Aavik E, Laine A et al. Therapeutic effects of rosuvastatin in hypercholesterolemic prediabetic mice in the absence of low density lipoprotein receptor. Biochimica et biophysica acta. General subjects 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508567
  3. Abdeen A, Aboubakr M, Elgazzar D et al. Rosuvastatin attenuates piroxicam-mediated gastric ulceration and hepato-renal toxicity in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 110:895-905. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572194
  4. Guo X, Wang L, Xia X et al. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019; 109:1445-1453. http://www.ncbi.nlm.nih.gov/pubmed/?term=30551396
  5. Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovascular diabetology 2018; 17:155. http://www.ncbi.nlm.nih.gov/pubmed/?term=30518364
  6. Du Y, Wang S, Chen Z et al. Association of SLCO1B1 polymorphisms and atorvastatin safety and efficacy: A meta-analysis. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30569848
  7. Mamdooh N, Kasabri V, Al-Hiari Y et al. Evaluation of selected commercial pharmacotherapeutic drugs as potential pancreatic lipase inhibitors and antiproliferative compounds. Drug development research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511444
  8. Dang H, Song B, Dong R, Zhang H. Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II. Experimental and therapeutic medicine 2018; 16:5286-5297. http://www.ncbi.nlm.nih.gov/pubmed/?term=30542486
  9. Kogawa AC, Pires A, Salgado HRN. Atorvastatin: A Review of Analytical Methods for Pharmaceutical Quality Control and Monitoring. J AOAC Int 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563586
  10. Sokalska A, Hawkins AB, Yamaguchi T, Duleba AJ. Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells. Journal of assisted reproduction and genetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30554393
  11. Yamaguchi K, Wakatsuki T, Niki T et al. Observation of short-term atorvastatin-induced changes in coronary arterial plaque properties using integrated backscatter intravascular ultrasound in a patient. Journal of cardiology cases 2011; 3:e111-e114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532851
  12. Gao G, Jiang S, Ge L et al. Atorvastatin improves doxorubicin-induced cardiac dysfunction by modulating Hsp70, Akt and MAPK signalling pathways. Journal of cardiovascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540688
  13. Akbari H, Asadikaram G, Vakili S, Masoumi M. Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30548657
  14. Cheng WP, Lo HM, Wang BW et al. Effect of atorvastatin on cardiomyocyte hypertrophy through suppressing MURC induced by volume overload and cyclic stretch. Journal of cellular and molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511410
  15. Rinella ME, Trotter JF, Abdelmalek MF et al. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis. J Hepatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30529590
  16. Zhu YC, Jiang XZ, Bai QK et al. Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563776
  17. Orsi FA, Biedermann JS, Kruip M et al. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. Journal of thrombosis and haemostasis : JTH 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30565854
  18. Raber L, Koskinas KC, Yamaji K et al. Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30553686
  19. Xiao Y, He S, Zhang Z et al. Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies. Medical science monitor : international medical journal of experimental and clinical research 2018; 24:9166-9176. http://www.ncbi.nlm.nih.gov/pubmed/?term=30557296
  20. Park MW, Park GM, Han S et al. Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis. PLoS One 2018; 13:e0207889. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532220

Basic science

  1. Singh F, Zoll J, Duthaler U et al. PGC-1beta modulates statin-associated myotoxicity in mice. Archives of toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511338
  2. Hasanvand A, Ahmadizar F, Abbaszadeh A et al. The Antinociceptive Effects of Rosuvastatin in Chronic Constriction Injury Model of Male Rats. Basic and clinical neuroscience 2018; 9:251-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=30519383
  3. Kim WH, Lee CH, Han JH et al. C/EBP homologous protein deficiency inhibits statin-induced myotoxicity. Biochem Biophys Res Commun 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528737
  4. Abdeen A, Aboubakr M, Elgazzar D et al. Rosuvastatin attenuates piroxicam-mediated gastric ulceration and hepato-renal toxicity in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 110:895-905. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572194
  5. El-Seweidy MM, Sarhan Amin R, Husseini Atteia H et al. Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 110:456-464. http://www.ncbi.nlm.nih.gov/pubmed/?term=30530048
  6. Guo X, Wang L, Xia X et al. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019; 109:1445-1453. http://www.ncbi.nlm.nih.gov/pubmed/?term=30551396
  7. Palko-Labuz A, Sroda-Pomianek K, Wesolowska O et al. MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019; 109:1511-1522. http://www.ncbi.nlm.nih.gov/pubmed/?term=30551403
  8. Otrocka-Domagala I, Pazdzior-Czapula K, Maslanka T. Simvastatin Impairs the Inflammatory and Repair Phases of the Postinjury Skeletal Muscle Regeneration. BioMed research international 2018; 2018:7617312. http://www.ncbi.nlm.nih.gov/pubmed/?term=30519583
  9. Milenkovic U, Ilg MM, Zuccato C et al. Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation. BJU international 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30536599
  10. Yan J, Qiao L, Wu J et al. Simvastatin Protects Dopaminergic Neurons Against MPP+-Induced Oxidative Stress and Regulates the Endogenous Anti-Oxidant System Through ERK. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 51:1957-1968. http://www.ncbi.nlm.nih.gov/pubmed/?term=30513525
  11. Leite ML, Soares DG, de Oliveira Duque CC et al. Positive influence of simvastatin used as adjuvant agent for cavity lining. Clinical oral investigations 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552591
  12. Anzilaggo D, O'Reilly Beringhs A, Pezzini BR et al. Liquisolid systems: Understanding the impact of drug state (solution or dispersion), nonvolatile solvent and coating material on simvastatin apparent aqueous solubility and flowability. Colloids and surfaces. B, Biointerfaces 2018; 175:36-43. http://www.ncbi.nlm.nih.gov/pubmed/?term=30517903
  13. Mehanna MM, Shabarek MI, El-Maradni HA. Spray-Dried pH Sensitive Microparticles: Effectual Methodology to Ameliorate the Bioavailability of Acid Labile Pravastatin. Drug development and industrial pharmacy 2018:1. http://www.ncbi.nlm.nih.gov/pubmed/?term=30575415
  14. Mamdooh N, Kasabri V, Al-Hiari Y et al. Evaluation of selected commercial pharmacotherapeutic drugs as potential pancreatic lipase inhibitors and antiproliferative compounds. Drug development research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511444
  15. Dang H, Song B, Dong R, Zhang H. Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II. Experimental and therapeutic medicine 2018; 16:5286-5297. http://www.ncbi.nlm.nih.gov/pubmed/?term=30542486
  16. Ali M, Jackson-Bey T, Al-Hendy A. Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertility and sterility 2018; 110:1272-1273. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503124
  17. Malik M, Britten J, Borahay M et al. Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production. Fertility and sterility 2018; 110:1398-1407.e1391. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503138
  18. Yang CN, Kok SH, Wang HW et al. Simvastatin alleviates bone resorption in apical periodontitis possibly by inhibition of mitophagy-related osteoblast apoptosis. International endodontic journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30537112
  19. Wang CZ, Wang YH, Lin CW et al. Combination of a Bioceramic Scaffold and Simvastatin Nanoparticles as a Synthetic Alternative to Autologous Bone Grafting. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=30567319
  20. Mansouri E, Assarehzadegan MA, Nejad-Dehbashi F, Kooti W. Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats. Iranian journal of pharmaceutical research : IJPR 2018; 17:1413-1419. http://www.ncbi.nlm.nih.gov/pubmed/?term=30568699
  21. Sato T, Arakawa M, Tashima Y et al. Statins Reduce Thoracic Aortic Aneurysm Growth in Marfan Syndrome Mice via Inhibition of the Ras-Induced ERK (Extracellular Signal-Regulated Kinase) Signaling Pathway. J Am Heart Assoc 2018; 7:e008543. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571378
  22. Kogawa AC, Pires A, Salgado HRN. Atorvastatin: A Review of Analytical Methods for Pharmaceutical Quality Control and Monitoring. J AOAC Int 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563586
  23. Sokalska A, Hawkins AB, Yamaguchi T, Duleba AJ. Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells. Journal of assisted reproduction and genetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30554393
  24. Farsani BE, Karimi S, Mansouri E. Pravastatin attenuates testicular damage induced by doxorubicin - a stereological and histopatological study. Journal of basic and clinical physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30530881
  25. Yuan X, Zhang M, Wang Y et al. Using Co-Axial Electrospray Deposition to Eliminate Burst Release of Simvastatin From Microparticles and to Enhance Induced Osteogenesis. Journal of biomaterials science. Polymer edition 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572791
  26. Gao G, Jiang S, Ge L et al. Atorvastatin improves doxorubicin-induced cardiac dysfunction by modulating Hsp70, Akt and MAPK signalling pathways. Journal of cardiovascular pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540688
  27. Cheng WP, Lo HM, Wang BW et al. Effect of atorvastatin on cardiomyocyte hypertrophy through suppressing MURC induced by volume overload and cyclic stretch. Journal of cellular and molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511410
  28. Lorza-Gil E, de Souza JC, Garcia-Arevalo M et al. Coenzyme Q10 protects against beta-cell toxicity induced by pravastatin treatment of hypercholesterolemia. Journal of cellular physiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30536661
  29. Zhang Y, Fang Q, Niu K et al. Time-dependently slow-released multiple-drug eluting external sheath for efficient long-term inhibition of saphenous vein graft failure. J Control Release 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30521829
  30. Gonen A, Choi SH, Miu P et al. A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563909
  31. Kaminska M, Aliko A, Hellvard A et al. Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas Gingivalis. Journal of periodontology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30506795
  32. Nonaka K, Ozaki Y, Ito K et al. Endurance exercise increases the protein levels of PGC-1alpha and respiratory chain complexes in mouse skeletal muscle during atorvastatin administration. The journal of physiological sciences : JPS 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30536041
  33. Ritter P, Yousefi K, Ramirez J et al. LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring. Journal of visualized experiments : JoVE 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30507918
  34. Xu HY, Xue JX, Gao H et al. Fluvastatin-mediated down-regulation of SATB1 affects aggressive phenotypes of human non-small-cell lung cancer cell line H292. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30557545
  35. Jiang SY, Li H, Tang JJ et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nature communications 2018; 9:5138. http://www.ncbi.nlm.nih.gov/pubmed/?term=30510211
  36. Baliga M, Chakraborty S, Kumari T et al. Is there a role for PRF with simvastatin in stage I osteoradionecrosis? Oral oncology 2018; 87:177-178. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527236
  37. Zamani M, Shirinzadeh A, Aghajanzadeh M et al. In Vivo Study of mPEG-PCL as a Nanocarriers for Anti-Inflammatory Drug Delivery of Simvastatin. Pharmaceutical development and technology 2018:1-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=30516412
  38. Wang L, Yuan M, Zheng J. Crystal structure of the condensation domain from lovastatin polyketide synthase. Synthetic and systems biotechnology 2019; 4:10-15. http://www.ncbi.nlm.nih.gov/pubmed/?term=30533541

Cancer

  1. Palko-Labuz A, Sroda-Pomianek K, Wesolowska O et al. MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019; 109:1511-1522. http://www.ncbi.nlm.nih.gov/pubmed/?term=30551403
  2. Gachpazan M, Kashani H, Khazaei M et al. The impact of statin therapy on survival of patients with gastrointestinal cancer. Current drug targets 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30539694
  3. Ali M, Jackson-Bey T, Al-Hendy A. Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertility and sterility 2018; 110:1272-1273. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503124
  4. Malik M, Britten J, Borahay M et al. Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production. Fertility and sterility 2018; 110:1398-1407.e1391. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503138
  5. Sokalska A, Hawkins AB, Yamaguchi T, Duleba AJ. Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells. Journal of assisted reproduction and genetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30554393
  6. Xu HY, Xue JX, Gao H et al. Fluvastatin-mediated down-regulation of SATB1 affects aggressive phenotypes of human non-small-cell lung cancer cell line H292. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30557545
  7. Ung MH, MacKenzie TA, Onega TL et al. Statins associate with improved mortality among patients with certain histological subtypes of lung cancer. Lung cancer (Amsterdam, Netherlands) 2018; 126:89-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527197
  8. Kruk PJ. Beneficial effect of additional treatment with widely available anticancer agents in advanced small lung cell carcinoma: A case report. Molecular and clinical oncology 2018; 9:647-650. http://www.ncbi.nlm.nih.gov/pubmed/?term=30546895
  9. Baliga M, Chakraborty S, Kumari T et al. Is there a role for PRF with simvastatin in stage I osteoradionecrosis? Oral oncology 2018; 87:177-178. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527236
  10. Farooqi MAM, Malhotra N, Mukherjee SD et al. Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2018; 13:e0209486. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571754
  11. Seliger C, Schaertl J, Gerken M et al. Use of statins or NSAIDs and survival of patients with high-grade glioma. PLoS One 2018; 13:e0207858. http://www.ncbi.nlm.nih.gov/pubmed/?term=30507932
  12. Anderson-Carter I, Posielski N, Liou JI et al. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urologic oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528885

Children

  1. Wagner JB, Abdel-Rahman S, Gaedigk R et al. Impact of genetic variation on pravastatin systemic exposure in pediatric hypercholesterolemia. Clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30549267

CVD

  1. Shiga Y, Miura SI, Nishikawa H et al. Regression of coronary plaque after coronary artery bypass graft. Journal of cardiology cases 2012; 5:e92-e95. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532913
  2. Xiao Y, He S, Zhang Z et al. Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies. Medical science monitor : international medical journal of experimental and clinical research 2018; 24:9166-9176. http://www.ncbi.nlm.nih.gov/pubmed/?term=30557296
  3. Dyrbus K, Gasior M, Desperak P et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. Pharmacol Res 2018; 139:460-466. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527895
  4. Cho YK, Nam CW, Koo BK et al. Usefulness of baseline statin therapy in non-obstructive coronary artery disease by coronary computed tomographic angiography: From the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) study. PLoS One 2018; 13:e0207194. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540755
  5. Caussy C, Charriere S, Moulin P. Statins in secondary prevention of cardiovascular risk. Rev Prat 2016; 66:322-326. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512646

Endothelium/inflammation

  1. Lee SH, Choi JH. Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy. Animal cells and systems 2018; 22:390-399. http://www.ncbi.nlm.nih.gov/pubmed/?term=30533261
  2. El-Seweidy MM, Sarhan Amin R, Husseini Atteia H et al. Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 110:456-464. http://www.ncbi.nlm.nih.gov/pubmed/?term=30530048
  3. Jialal I, Chaudhuri A. Targeting inflammation to reduce ASCVD in type 2 diabetes. Journal of diabetes and its complications 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30514609
  4. Schultz NEO, Hasseldam H, Rasmussen RS et al. Statin treatment before stroke reduces pro-inflammatory cytokine levels after stroke. Neurol Res 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30574850
  5. Zamani M, Shirinzadeh A, Aghajanzadeh M et al. In Vivo Study of mPEG-PCL as a Nanocarriers for Anti-Inflammatory Drug Delivery of Simvastatin. Pharmaceutical development and technology 2018:1-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=30516412
  6. Tabrizi R, Tamtaji OR, Mirhosseini N et al. The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30576798 

Ethnicity

  1. Blais JE, Chan EW, Law SWY et al. Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004-2015. Atherosclerosis 2018; 280:174-182. http://www.ncbi.nlm.nih.gov/pubmed/?term=30529830
  2. Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovascular diabetology 2018; 17:155. http://www.ncbi.nlm.nih.gov/pubmed/?term=30518364
  3. Teramoto T, Kiyosue A, Ishigaki Y et al. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON. J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30509509
  4. Sisa I. Gender differences in cardiovascular risk assessment in elderly adults in Ecuador: evidence from a national survey. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30518558
  5. Qamar A, Giugliano RP, Keech AC et al. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540337
  6. Basu S, Wagner RG, Sewpaul R et al. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. The Lancet. Global health 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528531
  7. Dyrbus K, Gasior M, Desperak P et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. Pharmacol Res 2018; 139:460-466. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527895
  8. Park MW, Park GM, Han S et al. Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis. PLoS One 2018; 13:e0207889. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532220
  9. Jiang J, Zhou YJ, Li JJ et al. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study. Therapeutics and clinical risk management 2018; 14:2255-2264. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532548
  10. Kocyigit D, Tokgozoglu L, Kayikcioglu M et al. Is there a gender gap in secondary prevention of coronary artery disease in Turkey? Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2018; 46:683-691. http://www.ncbi.nlm.nih.gov/pubmed/?term=30516526 

FH

  1. Shirahama R, Ono T, Nagamatsu S et al. Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation. Intern Med 2018; 57:3551-3557. http://www.ncbi.nlm.nih.gov/pubmed/?term=30555118
  2. Vuorio A, Kovanen PT. Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters. Nutrients 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30513705

Genetics

  1. Sliz E, Kettunen J, Holmes MV et al. Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. Circulation 2018; 138:2499-2512. http://www.ncbi.nlm.nih.gov/pubmed/?term=30525347
  2. Wagner JB, Abdel-Rahman S, Gaedigk R et al. Impact of genetic variation on pravastatin systemic exposure in pediatric hypercholesterolemia. Clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30549267
  3. Du Y, Wang S, Chen Z et al. Association of SLCO1B1 polymorphisms and atorvastatin safety and efficacy: A meta-analysis. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30569848
  4. Akbari H, Asadikaram G, Vakili S, Masoumi M. Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30548657

Guidelines

  1. Ennezat PV, Le Jemtel T, Cosgrove S et al. Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. Acta Cardiol 2018:1-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30513258
  2. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Circulation 2018:Cir0000000000000624. http://www.ncbi.nlm.nih.gov/pubmed/?term=30565953
  3. Kakadiaris IA, Vrigkas M, Yen AA et al. Machine Learning Outperforms ACC / AHA CVD Risk Calculator in MESA. J Am Heart Assoc 2018; 7:e009476. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571498
  4. Sisa I. Gender differences in cardiovascular risk assessment in elderly adults in Ecuador: evidence from a national survey. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30518558
  5. Johns I, Moschonas KE, Medina J et al. Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study. Open heart 2018; 5:e000849. http://www.ncbi.nlm.nih.gov/pubmed/?term=30564373

LDL- related parameters

  1. Aguiar A, Giaquinto PC. Low cholesterol is not always good: low cholesterol levels are associated with decreased serotonin and increased aggression in fish. Biology open 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30530746
  2. Schwaab B, Zeymer U, Jannowitz C et al. Improvement of low-density lipoprotein cholesterol target achievement rates through cardiac rehabilitation for patients after ST elevation myocardial infarction or non-ST elevation myocardial infarction in Germany: Results of the PATIENT CARE registry. Eur J Prev Cardiol 2018:2047487318817082. http://www.ncbi.nlm.nih.gov/pubmed/?term=30509144
  3. Ahmed O, Littmann K, Gustafsson U et al. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. J Am Heart Assoc 2018; 7:e009876. http://www.ncbi.nlm.nih.gov/pubmed/?term=30561264
  4. Gonen A, Choi SH, Miu P et al. A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563909
  5. Qamar A, Giugliano RP, Keech AC et al. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540337
  6. Choi HD, Chae SM. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e13593. http://www.ncbi.nlm.nih.gov/pubmed/?term=30558030
  7. Klein R, Lee KE, Tsai MY et al. Oxidized Low-Density Lipoprotein and the Incidence of Age-related Macular Degeneration. Ophthalmology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572074
  8. Cariou B, Smati S. LDL-cholesterol hypothesis:the lower is trully better. Rev Prat 2016; 66:317-321. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512645
  9. Caussy C, Charriere S, Moulin P. Statins in secondary prevention of cardiovascular risk. Rev Prat 2016; 66:322-326. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512646
  10. Sahebkar A, Simental-Mendia LE, Pirro M et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Scientific reports 2018; 8:17887. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552391
  11. Jiang J, Zhou YJ, Li JJ et al. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study. Therapeutics and clinical risk management 2018; 14:2255-2264. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532548

Lifestyle

  1. Yeager R, Riggs DW, DeJarnett N et al. Association Between Residential Greenness and Cardiovascular Disease Risk. J Am Heart Assoc 2018; 7:e009117. http://www.ncbi.nlm.nih.gov/pubmed/?term=30561265
  2. Nonaka K, Ozaki Y, Ito K et al. Endurance exercise increases the protein levels of PGC-1alpha and respiratory chain complexes in mouse skeletal muscle during atorvastatin administration. The journal of physiological sciences : JPS 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30536041
  3. Vuorio A, Kovanen PT. Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters. Nutrients 2018; 10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30513705

Meta-analyses

  1. Xiao Y, He S, Zhang Z et al. Effect of High-Dose Statin Pretreatment for Myocardial Perfusion in Patients Receiving Percutaneous Coronary Intervention (PCI): A Meta-Analysis of 15 Randomized Studies. Medical science monitor : international medical journal of experimental and clinical research 2018; 24:9166-9176. http://www.ncbi.nlm.nih.gov/pubmed/?term=30557296
  2. Choi HD, Chae SM. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e13593. http://www.ncbi.nlm.nih.gov/pubmed/?term=30558030
  3. Zeng H, Li Z, He G et al. Use of statins and the risk of delirium in critically ill and surgical patients: Protocol of a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e13679. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572490
  4. Tabrizi R, Tamtaji OR, Mirhosseini N et al. The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30576798
  5. Farooqi MAM, Malhotra N, Mukherjee SD et al. Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2018; 13:e0209486. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571754
  6. Sahebkar A, Simental-Mendia LE, Pirro M et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Scientific reports 2018; 8:17887. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552391 

Metabolic Syndrome - Diabetes

  1. Gurzeler E, Aavik E, Laine A et al. Therapeutic effects of rosuvastatin in hypercholesterolemic prediabetic mice in the absence of low density lipoprotein receptor. Biochimica et biophysica acta. General subjects 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508567
  2. Morville T, Dohlmann T, Kuhlman AB et al. Glucose homeostasis in statin users - the LIFESTAT study. Diabetes/metabolism research and reviews 2018:e3110. http://www.ncbi.nlm.nih.gov/pubmed/?term=30517978
  3. Jialal I, Chaudhuri A. Targeting inflammation to reduce ASCVD in type 2 diabetes. Journal of diabetes and its complications 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30514609
  4. Hemo B, Shahar DR, Geva D, Heymann AD. Adherence to quality of care measurements among 58,182 patients with new onset diabetes and its association with mortality. PLoS One 2018; 13:e0208539. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540832

New Treatments

  1. Koskinas KC, Windecker S, Buhayer A et al. Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial. Clin Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30421481
  2. Szarek M, White HD, Schwartz GG et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. J Am Coll Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30428396
  3. Khoshnejad M, Patel A, Wojtak K et al. Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics. Molecular therapy : the journal of the American Society of Gene Therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30449662
  4. Bhatt DL, Steg PG, Miller M et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30415628
  5. Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30420622
  6. Kosmas CE, Silverio D, Ovalle J et al. Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient preference and adherence 2018; 12:2263-2266. http://www.ncbi.nlm.nih.gov/pubmed/?term=30464416

Other

  1. Dekkers CC, Westerink J, Hoepelman AIM, Arends JE. Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence. AIDS reviews 2018; 20:205-219. http://www.ncbi.nlm.nih.gov/pubmed/?term=30548018
  2. Yebyo HG, Aschmann HE, Puhan MA. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Annals of internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508425
  3. Rosenson RS, Colantonio LD, Burkholder GA et al. Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015. J Am Heart Assoc 2018; 7:e010345. http://www.ncbi.nlm.nih.gov/pubmed/?term=30526249
  4. Yagi S, Fujimura M, Akaike M et al. Increase in serum triglyceride was associated with coronary plaque vulnerability in a patient with rheumatoid arthritis. Journal of cardiology cases 2014; 10:54-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30546505
  5. Ritter P, Yousefi K, Ramirez J et al. LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring. Journal of visualized experiments : JoVE 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30507918
  6. Kutner JS, Abernethy AP. Coding Error Resulting in Change in Secondary Outcome Scores in Trial of Safety and Benefit of Discontinuing Statin Therapy Among Terminally Ill Patients. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508023

Pleiotropic effects of statins

  1. Hasanvand A, Ahmadizar F, Abbaszadeh A et al. The Antinociceptive Effects of Rosuvastatin in Chronic Constriction Injury Model of Male Rats. Basic and clinical neuroscience 2018; 9:251-260. http://www.ncbi.nlm.nih.gov/pubmed/?term=30519383
  2. Gurzeler E, Aavik E, Laine A et al. Therapeutic effects of rosuvastatin in hypercholesterolemic prediabetic mice in the absence of low density lipoprotein receptor. Biochimica et biophysica acta. General subjects 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508567
  3. Alshaikh HN, Bohsali F, Gani F et al. Statin intensity and postoperative mortality following open repair of intact abdominal aortic aneurysm. BJS open 2018; 2:411-418. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511041
  4. Yan J, Qiao L, Wu J et al. Simvastatin Protects Dopaminergic Neurons Against MPP+-Induced Oxidative Stress and Regulates the Endogenous Anti-Oxidant System Through ERK. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; 51:1957-1968. http://www.ncbi.nlm.nih.gov/pubmed/?term=30513525
  5. Leite ML, Soares DG, de Oliveira Duque CC et al. Positive influence of simvastatin used as adjuvant agent for cavity lining. Clinical oral investigations 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552591
  6. Gachpazan M, Kashani H, Khazaei M et al. The impact of statin therapy on survival of patients with gastrointestinal cancer. Current drug targets 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30539694
  7. Mamdooh N, Kasabri V, Al-Hiari Y et al. Evaluation of selected commercial pharmacotherapeutic drugs as potential pancreatic lipase inhibitors and antiproliferative compounds. Drug development research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511444
  8. Dang H, Song B, Dong R, Zhang H. Atorvastatin reverses the dysfunction of human umbilical vein endothelial cells induced by angiotensin II. Experimental and therapeutic medicine 2018; 16:5286-5297. http://www.ncbi.nlm.nih.gov/pubmed/?term=30542486
  9. Jia L, Wang L, Liu W et al. Erratum: Fluvastatin inhibits cardiomyocyte apoptosis after myocardial infarction through Toll pathway. Experimental and therapeutic medicine 2018; 16:5424. http://www.ncbi.nlm.nih.gov/pubmed/?term=30555540
  10. Ali M, Jackson-Bey T, Al-Hendy A. Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertility and sterility 2018; 110:1272-1273. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503124
  11. Malik M, Britten J, Borahay M et al. Simvastatin, at clinically relevant concentrations, affects human uterine leiomyoma growth and extracellular matrix production. Fertility and sterility 2018; 110:1398-1407.e1391. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503138
  12. Chen MJ, Bala A, Huddleston JI, 3rd et al. Statin use is associated with less postoperative cardiac arrhythmia after total hip arthroplasty. Hip international : the journal of clinical and experimental research on hip pathology and therapy 2018:1120700018816091. http://www.ncbi.nlm.nih.gov/pubmed/?term=30526117
  13. Yang CN, Kok SH, Wang HW et al. Simvastatin alleviates bone resorption in apical periodontitis possibly by inhibition of mitophagy-related osteoblast apoptosis. International endodontic journal 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30537112
  14. Wang CZ, Wang YH, Lin CW et al. Combination of a Bioceramic Scaffold and Simvastatin Nanoparticles as a Synthetic Alternative to Autologous Bone Grafting. Int J Mol Sci 2018; 19. http://www.ncbi.nlm.nih.gov/pubmed/?term=30567319
  15. Mansouri E, Assarehzadegan MA, Nejad-Dehbashi F, Kooti W. Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats. Iranian journal of pharmaceutical research : IJPR 2018; 17:1413-1419. http://www.ncbi.nlm.nih.gov/pubmed/?term=30568699
  16. Sato T, Arakawa M, Tashima Y et al. Statins Reduce Thoracic Aortic Aneurysm Growth in Marfan Syndrome Mice via Inhibition of the Ras-Induced ERK (Extracellular Signal-Regulated Kinase) Signaling Pathway. J Am Heart Assoc 2018; 7:e008543. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571378
  17. Sokalska A, Hawkins AB, Yamaguchi T, Duleba AJ. Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells. Journal of assisted reproduction and genetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30554393
  18. Farsani BE, Karimi S, Mansouri E. Pravastatin attenuates testicular damage induced by doxorubicin - a stereological and histopatological study. Journal of basic and clinical physiology and pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30530881
  19. Yuan X, Zhang M, Wang Y et al. Using Co-Axial Electrospray Deposition to Eliminate Burst Release of Simvastatin From Microparticles and to Enhance Induced Osteogenesis. Journal of biomaterials science. Polymer edition 2018:1-37. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572791
  20. Giannopoulos G, Vrachatis D, Kossyvakis C et al. Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation. Journal of cardiovascular pharmacology 2018; 72:285-290. http://www.ncbi.nlm.nih.gov/pubmed/?term=30520854
  21. Cheng WP, Lo HM, Wang BW et al. Effect of atorvastatin on cardiomyocyte hypertrophy through suppressing MURC induced by volume overload and cyclic stretch. Journal of cellular and molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511410
  22. Zhang Y, Fang Q, Niu K et al. Time-dependently slow-released multiple-drug eluting external sheath for efficient long-term inhibition of saphenous vein graft failure. J Control Release 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30521829
  23. Rinella ME, Trotter JF, Abdelmalek MF et al. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis. J Hepatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30529590
  24. Kaminska M, Aliko A, Hellvard A et al. Effects of statins on multispecies oral biofilm identify simvastatin as a drug candidate targeting Porphyromonas Gingivalis. Journal of periodontology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30506795
  25. Orsi FA, Biedermann JS, Kruip M et al. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. Journal of thrombosis and haemostasis : JTH 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30565854
  26. Xu HY, Xue JX, Gao H et al. Fluvastatin-mediated down-regulation of SATB1 affects aggressive phenotypes of human non-small-cell lung cancer cell line H292. Life sciences 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30557545
  27. Ung MH, MacKenzie TA, Onega TL et al. Statins associate with improved mortality among patients with certain histological subtypes of lung cancer. Lung cancer (Amsterdam, Netherlands) 2018; 126:89-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527197
  28. Pantea M, Negovan A, Voidazan S et al. Statins and gastroduodenal endoscopic lesions: A case-control study. Medicine (Baltimore) 2018; 97:e13579. http://www.ncbi.nlm.nih.gov/pubmed/?term=30558024
  29. Schultz JL, Nopoulos PC, Killoran A, Kamholz JA. Statin use and delayed onset of Huntington's disease. Movement disorders : official journal of the Movement Disorder Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30576007
  30. Baliga M, Chakraborty S, Kumari T et al. Is there a role for PRF with simvastatin in stage I osteoradionecrosis? Oral oncology 2018; 87:177-178. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527236
  31. Zamani M, Shirinzadeh A, Aghajanzadeh M et al. In Vivo Study of mPEG-PCL as a Nanocarriers for Anti-Inflammatory Drug Delivery of Simvastatin. Pharmaceutical development and technology 2018:1-25. http://www.ncbi.nlm.nih.gov/pubmed/?term=30516412
  32. Tabrizi R, Tamtaji OR, Mirhosseini N et al. The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30576798
  33. Seliger C, Schaertl J, Gerken M et al. Use of statins or NSAIDs and survival of patients with high-grade glioma. PLoS One 2018; 13:e0207858. http://www.ncbi.nlm.nih.gov/pubmed/?term=30507932
  34. Anderson-Carter I, Posielski N, Liou JI et al. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urologic oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528885

Primary Prevention

  1. Yebyo HG, Aschmann HE, Puhan MA. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Annals of internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508425
  2. Buhse S, Kuniss N, Liethmann K et al. Informed shared decision-making programme for patients with type 2 diabetes in primary care: cluster randomised controlled trial. BMJ Open 2018; 8:e024004. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552272
  3. Pais P, Jung H, Dans A et al. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. Eur J Prev Cardiol 2018:2047487318819019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30537846
  4. Beliard-Lasserre S. Should we prescribe statins for primary prevention of cardiovascular risk? Rather yes. Rev Prat 2016; 66:332-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512650
  5. Lecerf JM. Should we prescribe statins for primary prevention of cardiovascular risk? Rather no. Rev Prat 2016; 66:334-337. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512651

Registry data

  1. Blais JE, Chan EW, Law SWY et al. Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004-2015. Atherosclerosis 2018; 280:174-182. http://www.ncbi.nlm.nih.gov/pubmed/?term=30529830
  2. Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovascular diabetology 2018; 17:155. http://www.ncbi.nlm.nih.gov/pubmed/?term=30518364
  3. Morville T, Dohlmann T, Kuhlman AB et al. Glucose homeostasis in statin users - the LIFESTAT study. Diabetes/metabolism research and reviews 2018:e3110. http://www.ncbi.nlm.nih.gov/pubmed/?term=30517978
  4. Schwaab B, Zeymer U, Jannowitz C et al. Improvement of low-density lipoprotein cholesterol target achievement rates through cardiac rehabilitation for patients after ST elevation myocardial infarction or non-ST elevation myocardial infarction in Germany: Results of the PATIENT CARE registry. Eur J Prev Cardiol 2018:2047487318817082. http://www.ncbi.nlm.nih.gov/pubmed/?term=30509144
  5. Rosenson RS, Colantonio LD, Burkholder GA et al. Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV--Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015. J Am Heart Assoc 2018; 7:e010345. http://www.ncbi.nlm.nih.gov/pubmed/?term=30526249
  6. Ladapo JA, Pfeifer JM, Pitcavage JM et al. Quantifying Sex Differences in Cardiovascular Care Among Patients Evaluated for Suspected Ischemic Heart Disease. Journal of women's health (2002) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30543478
  7. Basu S, Wagner RG, Sewpaul R et al. Implications of scaling up cardiovascular disease treatment in South Africa: a microsimulation and cost-effectiveness analysis. The Lancet. Global health 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528531
  8. Ung MH, MacKenzie TA, Onega TL et al. Statins associate with improved mortality among patients with certain histological subtypes of lung cancer. Lung cancer (Amsterdam, Netherlands) 2018; 126:89-96. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527197
  9. Schultz JL, Nopoulos PC, Killoran A, Kamholz JA. Statin use and delayed onset of Huntington's disease. Movement disorders : official journal of the Movement Disorder Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30576007
  10. Johns I, Moschonas KE, Medina J et al. Risk classification in primary prevention of CVD according to QRISK2 and JBS3 'heart age', and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study. Open heart 2018; 5:e000849. http://www.ncbi.nlm.nih.gov/pubmed/?term=30564373
  11. Kinsey TL, Sturmer T, Poole C et al. Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30565779
  12. Dyrbus K, Gasior M, Desperak P et al. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. Pharmacol Res 2018; 139:460-466. http://www.ncbi.nlm.nih.gov/pubmed/?term=30527895
  13. Hemo B, Shahar DR, Geva D, Heymann AD. Adherence to quality of care measurements among 58,182 patients with new onset diabetes and its association with mortality. PLoS One 2018; 13:e0208539. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540832
  14. Park MW, Park GM, Han S et al. Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis. PLoS One 2018; 13:e0207889. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532220
  15. Seliger C, Schaertl J, Gerken M et al. Use of statins or NSAIDs and survival of patients with high-grade glioma. PLoS One 2018; 13:e0207858. http://www.ncbi.nlm.nih.gov/pubmed/?term=30507932
  16. Borges IBP, Shinjo SK. Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies. Rheumatology international 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30519709
  17. Jiang J, Zhou YJ, Li JJ et al. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study. Therapeutics and clinical risk management 2018; 14:2255-2264. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532548
  18. Anderson-Carter I, Posielski N, Liou JI et al. The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urologic oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528885

Renal Disease

  1. Mansouri E, Assarehzadegan MA, Nejad-Dehbashi F, Kooti W. Effects of Pravastatin in Adriamycin-Induced Nephropathy in Rats. Iranian journal of pharmaceutical research : IJPR 2018; 17:1413-1419. http://www.ncbi.nlm.nih.gov/pubmed/?term=30568699
  2. Al-Taani GM, Al-Azzam SI, Alzoubi KH, Aldeyab MA. Which drugs cause treatment-related problems? Analysis of 10,672 problems within the outpatient setting. Therapeutics and clinical risk management 2018; 14:2273-2281. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532550

Reviews

  1. Ennezat PV, Le Jemtel T, Cosgrove S et al. Outcome postponement as a potential patient centred measure of therapeutic benefit: examples in cardiovascular medicine. Acta Cardiol 2018:1-10. http://www.ncbi.nlm.nih.gov/pubmed/?term=30513258
  2. Dekkers CC, Westerink J, Hoepelman AIM, Arends JE. Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence. AIDS reviews 2018; 20:205-219. http://www.ncbi.nlm.nih.gov/pubmed/?term=30548018
  3. Takata K, Nicholls SJ. Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. Am J Cardiovasc Drugs 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30565156
  4. Lee SH, Choi JH. Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy. Animal cells and systems 2018; 22:390-399. http://www.ncbi.nlm.nih.gov/pubmed/?term=30533261
  5. Yebyo HG, Aschmann HE, Puhan MA. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Annals of internal medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508425
  6. Gupta KK, Ali S, Sanghera RS. Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. Cardiology and therapy 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30543029
  7. Ali M, Jackson-Bey T, Al-Hendy A. Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertility and sterility 2018; 110:1272-1273. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503124
  8. Jialal I, Chaudhuri A. Targeting inflammation to reduce ASCVD in type 2 diabetes. Journal of diabetes and its complications 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30514609
  9. Feldman MD, Cabe AG, Milner TE. IVOCT Has a Bright Future in the Identification of Vulnerable Plaques. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30503625
  10. Kruk PJ. Beneficial effect of additional treatment with widely available anticancer agents in advanced small lung cell carcinoma: A case report. Molecular and clinical oncology 2018; 9:647-650. http://www.ncbi.nlm.nih.gov/pubmed/?term=30546895
  11. Ochs-Balcom HM, Nguyen LM, Ma C et al. Clinical Features Related to Statin-Associated Muscle Symptoms. Muscle Nerve 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30549046
  12. Farooqi MAM, Malhotra N, Mukherjee SD et al. Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2018; 13:e0209486. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571754
  13. Beliard-Lasserre S. Should we prescribe statins for primary prevention of cardiovascular risk? Rather yes. Rev Prat 2016; 66:332-334. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512650
  14. Cariou B, Smati S. LDL-cholesterol hypothesis:the lower is trully better. Rev Prat 2016; 66:317-321. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512645
  15. Caussy C, Charriere S, Moulin P. Statins in secondary prevention of cardiovascular risk. Rev Prat 2016; 66:322-326. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512646
  16. Lecerf JM. Should we prescribe statins for primary prevention of cardiovascular risk? Rather no. Rev Prat 2016; 66:334-337. http://www.ncbi.nlm.nih.gov/pubmed/?term=30512651
  17. Kocyigit D, Tokgozoglu L, Kayikcioglu M et al. Is there a gender gap in secondary prevention of coronary artery disease in Turkey? Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2018; 46:683-691. http://www.ncbi.nlm.nih.gov/pubmed/?term=30516526

Safety and side effects

  1. Singh F, Zoll J, Duthaler U et al. PGC-1beta modulates statin-associated myotoxicity in mice. Archives of toxicology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30511338
  2. Kim WH, Lee CH, Han JH et al. C/EBP homologous protein deficiency inhibits statin-induced myotoxicity. Biochem Biophys Res Commun 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528737
  3. Aguiar A, Giaquinto PC. Low cholesterol is not always good: low cholesterol levels are associated with decreased serotonin and increased aggression in fish. Biology open 2018; 7. http://www.ncbi.nlm.nih.gov/pubmed/?term=30530746
  4. Abdeen A, Aboubakr M, Elgazzar D et al. Rosuvastatin attenuates piroxicam-mediated gastric ulceration and hepato-renal toxicity in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 110:895-905. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572194
  5. Otrocka-Domagala I, Pazdzior-Czapula K, Maslanka T. Simvastatin Impairs the Inflammatory and Repair Phases of the Postinjury Skeletal Muscle Regeneration. BioMed research international 2018; 2018:7617312. http://www.ncbi.nlm.nih.gov/pubmed/?term=30519583
  6. Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. Cardiovascular diabetology 2018; 17:155. http://www.ncbi.nlm.nih.gov/pubmed/?term=30518364
  7. Wagner JB, Abdel-Rahman S, Gaedigk R et al. Impact of genetic variation on pravastatin systemic exposure in pediatric hypercholesterolemia. Clinical pharmacology and therapeutics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30549267
  8. Downs TN. Statins: The Burglar of Memory? The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2018; 33:706-710. http://www.ncbi.nlm.nih.gov/pubmed/?term=30545434
  9. Du Y, Wang S, Chen Z et al. Association of SLCO1B1 polymorphisms and atorvastatin safety and efficacy: A meta-analysis. Current pharmaceutical design 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30569848
  10. Morville T, Dohlmann T, Kuhlman AB et al. Glucose homeostasis in statin users - the LIFESTAT study. Diabetes/metabolism research and reviews 2018:e3110. http://www.ncbi.nlm.nih.gov/pubmed/?term=30517978
  11. Mori D, Kashihara Y, Yoshikado T et al. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers. Drug metabolism and pharmacokinetics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30528195
  12. Kandzia I, Kowar M, Frackowiak M, Jacobs AH. [Simvastatin-Induced Myopathy after Dose Increase]. Deutsche medizinische Wochenschrift (1946) 2018; 143:1791-1794. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508862
  13. Gosho M. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis. Fundamental & clinical pharmacology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30575126
  14. Lorza-Gil E, de Souza JC, Garcia-Arevalo M et al. Coenzyme Q10 protects against beta-cell toxicity induced by pravastatin treatment of hypercholesterolemia. Journal of cellular physiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30536661
  15. de Las Marinas Alvarez MD, Lopez Calatayud V, Solaz Garrido B et al. Moderate Asymptomatic Subacute Eosinophilia Secondary to Simvastatin Therapy. J Investig Allergol Clin Immunol 2018; 28:434-436. http://www.ncbi.nlm.nih.gov/pubmed/?term=30530396
  16. Kutner JS, Abernethy AP. Coding Error Resulting in Change in Secondary Outcome Scores in Trial of Safety and Benefit of Discontinuing Statin Therapy Among Terminally Ill Patients. JAMA Intern Med 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30508023
  17. Ochs-Balcom HM, Nguyen LM, Ma C et al. Clinical Features Related to Statin-Associated Muscle Symptoms. Muscle Nerve 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30549046
  18. Borges IBP, Shinjo SK. Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies. Rheumatology international 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30519709
  19. Al-Taani GM, Al-Azzam SI, Alzoubi KH, Aldeyab MA. Which drugs cause treatment-related problems? Analysis of 10,672 problems within the outpatient setting. Therapeutics and clinical risk management 2018; 14:2273-2281. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532550

Stroke and CNS

  1. Zhang H, Cui Y, Zhao Y et al. Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research : official journal of the Japanese Society of Hypertension 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552406
  2. Zhu YC, Jiang XZ, Bai QK et al. Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563776
  3. Zeng H, Li Z, He G et al. Use of statins and the risk of delirium in critically ill and surgical patients: Protocol of a systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e13679. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572490
  4. Schultz JL, Nopoulos PC, Killoran A, Kamholz JA. Statin use and delayed onset of Huntington's disease. Movement disorders : official journal of the Movement Disorder Society 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30576007
  5. Schultz NEO, Hasseldam H, Rasmussen RS et al. Statin treatment before stroke reduces pro-inflammatory cytokine levels after stroke. Neurol Res 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30574850
  6. Klein R, Lee KE, Tsai MY et al. Oxidized Low-Density Lipoprotein and the Incidence of Age-related Macular Degeneration. Ophthalmology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30572074 

Triglycerides/HDL

  1. Yagi S, Fujimura M, Akaike M et al. Increase in serum triglyceride was associated with coronary plaque vulnerability in a patient with rheumatoid arthritis. Journal of cardiology cases 2014; 10:54-57. http://www.ncbi.nlm.nih.gov/pubmed/?term=30546505

Trials

  1. Pagidipati NJ, Coles A, Hemal K et al. Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial. Am Heart J 2018; 208:28-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=30529930
  2. Pais P, Jung H, Dans A et al. Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. Eur J Prev Cardiol 2018:2047487318819019. http://www.ncbi.nlm.nih.gov/pubmed/?term=30537846
  3. Zhang H, Cui Y, Zhao Y et al. Effects of sartans and low-dose statins on cerebral white matter hyperintensities and cognitive function in older patients with hypertension: a randomized, double-blind and placebo-controlled clinical trial. Hypertension research : official journal of the Japanese Society of Hypertension 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30552406
  4. Ahmed O, Littmann K, Gustafsson U et al. Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients. J Am Heart Assoc 2018; 7:e009876. http://www.ncbi.nlm.nih.gov/pubmed/?term=30561264
  5. Teramoto T, Kiyosue A, Ishigaki Y et al. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON. J Cardiol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30509509
  6. Yamaguchi K, Wakatsuki T, Niki T et al. Observation of short-term atorvastatin-induced changes in coronary arterial plaque properties using integrated backscatter intravascular ultrasound in a patient. Journal of cardiology cases 2011; 3:e111-e114. http://www.ncbi.nlm.nih.gov/pubmed/?term=30532851
  7. Giannopoulos G, Vrachatis D, Kossyvakis C et al. Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation. Journal of cardiovascular pharmacology 2018; 72:285-290. http://www.ncbi.nlm.nih.gov/pubmed/?term=30520854
  8. Akbari H, Asadikaram G, Vakili S, Masoumi M. Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. Journal of cellular biochemistry 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30548657
  9. Pahor M, Anton SD, Beavers DP et al. Effect of losartan and fish oil on plasma IL-6 and mobility in older persons. The ENRGISE Pilot randomized clinical trial. J Gerontol A Biol Sci Med Sci 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30541065
  10. Rinella ME, Trotter JF, Abdelmalek MF et al. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with nonalcoholic steatohepatitis. J Hepatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30529590
  11. Zhu YC, Jiang XZ, Bai QK et al. Evaluating the Efficacy of Atorvastatin on Patients with Carotid Plaque by an Innovative Ultrasonography. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563776
  12. Orsi FA, Biedermann JS, Kruip M et al. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. Journal of thrombosis and haemostasis : JTH 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30565854
  13. Raber L, Koskinas KC, Yamaji K et al. Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study. JACC. Cardiovascular imaging 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30553686
  14. Qamar A, Giugliano RP, Keech AC et al. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA cardiology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540337
  15. Pantea M, Negovan A, Voidazan S et al. Statins and gastroduodenal endoscopic lesions: A case-control study. Medicine (Baltimore) 2018; 97:e13579. http://www.ncbi.nlm.nih.gov/pubmed/?term=30558024
  16. Schultz NEO, Hasseldam H, Rasmussen RS et al. Statin treatment before stroke reduces pro-inflammatory cytokine levels after stroke. Neurol Res 2018:1-9. http://www.ncbi.nlm.nih.gov/pubmed/?term=30574850
  17. Cho YK, Nam CW, Koo BK et al. Usefulness of baseline statin therapy in non-obstructive coronary artery disease by coronary computed tomographic angiography: From the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) study. PLoS One 2018; 13:e0207194. http://www.ncbi.nlm.nih.gov/pubmed/?term=30540755
  18. Kamal AK, Khalid W, Muqeet A et al. Making prescriptions "talk" to stroke and heart attack survivors to improve adherence: Results of a randomized clinical trial (The Talking Rx Study). PLoS One 2018; 13:e0197671. http://www.ncbi.nlm.nih.gov/pubmed/?term=30571697
  19. Shyamsundar M, O'Kane C, Perkins GD et al. Prevention of post-operative complications by using a HMG-CoA reductase inhibitor in patients undergoing one-lung ventilation for non-cardiac surgery: study protocol for a randomised controlled trial. Trials 2018; 19:690. http://www.ncbi.nlm.nih.gov/pubmed/?term=30563555

Women and elderly

  1. Sisa I. Gender differences in cardiovascular risk assessment in elderly adults in Ecuador: evidence from a national survey. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30518558
  2. Ladapo JA, Pfeifer JM, Pitcavage JM et al. Quantifying Sex Differences in Cardiovascular Care Among Patients Evaluated for Suspected Ischemic Heart Disease. Journal of women's health (2002) 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30543478
  3. Kinsey TL, Sturmer T, Poole C et al. Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=30565779
  4. Kocyigit D, Tokgozoglu L, Kayikcioglu M et al. Is there a gender gap in secondary prevention of coronary artery disease in Turkey? Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2018; 46:683-691. http://www.ncbi.nlm.nih.gov/pubmed/?term=30516526
 
 
 
 
 
 
 
Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.